Disc Medicine (IRON) soars 39% after bitopertin hits all Phase 3 endpoints in Apollo trial
What happened
Disc Medicine (IRON) announced that its investigational drug bitopertin met all primary and secondary endpoints in the Phase 3 Apollo trial in adults and adolescents with erythropoietic protoporphyria, a rare disorder causing severe light sensitivity. The stock surged more than 39% on Monday, making it the biggest gainer in the S&P 500 and Nasdaq 100 on a day when the broader market was rebounding off its worst weekly selloff since April 2025.
Why it matters & what’s next are part of Pro, along with the audio summary.
Start your free 14-day trialWho’s affected & sources
Who’s affected
- Disc Medicine (IRON): up 39%+ Monday, the day's top S&P 500/Nasdaq 100 gainer — trial success materially de-risks its lead asset
- Biotech/specialty pharma (XBI, peers): positive read-through for rare-disease trial readouts; reinforces that event-driven biotech moves remain intact in a risk-off tape
Sources